Lineage Cell Therapeutics Inc (AMEX:LCTX)’s traded shares stood at 0.71 million during the last session, with the company’s beta value hitting 1.19. At the close of trading, the stock’s price was $0.59, to imply an increase of 2.80% or $0.02 in intraday trading. The LCTX share’s 52-week high remains $1.61, putting it -172.88% down since that peak but still an impressive 18.64% since price per share fell to its 52-week low of $0.48. The company has a valuation of $129.48M, with an average of 2.85 million shares in intraday trading volume over the past 10 days and average of 2.29 million shares over the past 3 months.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
After registering a 2.80% upside in the last session, Lineage Cell Therapeutics Inc (LCTX) has traded red over the past five days. The 5-day price performance for the stock is 1.28%, and 17.48% over 30 days. With these gigs, the year-to-date price performance is 16.90%. Short interest in Lineage Cell Therapeutics Inc (AMEX:LCTX) saw shorts transact 15.94 million shares and set a 35.21 days time to cover.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Looking at statistics comparing Lineage Cell Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Lineage Cell Therapeutics Inc (LCTX) shares are -41.84% down over the last 6 months, with its year-to-date growth rate lower than industry average at 0.00% against 16.60%. The rating firms project that company’s revenue will shrink -7.73% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 1.62M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 1.36M.Earnings reports from the last fiscal year show that sales brought in 2.12M and 1.44M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -23.46% before dropping -5.75% in the following quarter.
LCTX Dividends
Lineage Cell Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Lineage Cell Therapeutics Inc insiders hold 0.44% of total outstanding shares, with institutional holders owning 50.56% of the shares at 50.79% float percentage. In total, 50.56% institutions holds shares in the company, led by BROADWOOD CAPITAL INC. As of 2024-06-30, the company held over 41.67 million shares (or 22.7798% of shares), all amounting to roughly $41.55 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 9.56 million shares, or about 5.2264% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $9.53 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Lineage Cell Therapeutics Inc (LCTX) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 4.42 shares. This is just over 2.00% of the total shares, with a market valuation of $2.59 million. Data from the same date shows that the other fund manager holds a little less at 3.68, or 1.67% of the shares, all valued at about 2.16 million.
